Wanbangde Pharmaceutical Group Co., Ltd. Announces Public Disclosure of the Environmental Impact Assessment for a New Project Producing 609 kg of Phloroglucinol Dihydrate Intermediate Annually

Home

About Us

• Company Profile

• HIstory

• Culture

• Honor

Products

• Cardiovascular series

• Psychiatry series

• Hepatobiliary, Gastroenterology Series

• Respiratory series

• Anti-infective virus series

• Other series

• Large Infusion Series

• Huabao Tong Series

• Active Pharmaceutical Ingredient Series

R&D

• Academician Expert Workstation

• Medical Research and Industry Alliance

News

• General News

• Party group dynamics

• Employee activity

HR

• Talent Strategy

• Company recruitment

Contact us

中文版